Antianginal Efficacy and Tolerability of Ranolazine as an Add‑on Drug to Concomitant Medications Primarily Metoprolol in Chronic Stable Angina Patients: A Prospective, Open‑Label Study

Abstract

Objective: To evaluate the efficacy and tolerability of ranolazine as an add‑on drug in chronic stable angina patients and the impact of ranolazine on the quality of life in chronic stable angina patients receiving other antianginal medications.Materials and Methods: It was a prospective, open‑label, hospital‑based study involving 144 patients with chronic stable angina. First group received either metoprolol 12.5 or 25 mg/day or other antianginal medications; if the symptoms persist, the dose of metoprolol was increased to 50 mg/day, and to the second group, ranolazine 500 mg BD or 1 g OD was added along with metoprolol or others if the anginal attacks were not subsiding. The patients were followed up to 6 months with electrocardiography, treadmill test, and quality of life questionnaire. Adverse events were recorded at each visit during the study.Results: There was a statistically significant reduction in weekly anginal frequency (P < 0.001) and improvement in an exercise tolerance in both the groups, but more in the ranolazine group. Adverse events reported were mild, infrequent.Conclusion: Ranolazine is could be used as an add‑on drug in chronic angina patients not improved with metoprolol or antianginal medications.

Keywords: Coronary artery disease; exercise tolerance; percutaneous intervention; quality of life; ranolazine